Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_assertion type Assertion NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_head.
- NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_assertion description "[before RRBSO and with no clinical signs of ovarian cancer) CA125 level was 9.0 U/ml (range 2-78) and was 10.0 U/ml (range 1-43) in 115 BRCA2 mutation carriers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_provenance.
- NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_assertion evidence source_evidence_literature NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_provenance.
- NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_assertion SIO_000772 24389956 NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_provenance.
- NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_assertion wasDerivedFrom befree-20150227 NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_provenance.
- NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_assertion wasGeneratedBy ECO_0000203 NP542817.RAioZKXYOw4eNZGCam0Y3_2FzYg5u0xAL8jf02n-7fzOs130_provenance.